Ascendance Biotechnology Inc., of Medford, Mass., said it executed a deal with GE Healthcare, providing Ascendance a right to manufacture, market and sell the GE Healthcare Cytiva brand of human stem cell-derived cardiomyocytes used for evaluating potential cardiotoxicity.